Short Interest in INVO Fertility, Inc (NASDAQ:IVF) Increases By 60.9%

INVO Fertility, Inc (NASDAQ:IVF) saw a significant growth in short interest in August. As of August 31st, there was short interest totaling 367,548 shares, a growth of 60.9% from the August 15th total of 228,460 shares. Currently, 14.7% of the shares of the stock are sold short. Based on an average daily volume of 11,714,828 shares, the days-to-cover ratio is currently 0.0 days.

Wall Street Analysts Forecast Growth

IVF has been the subject of a number of recent research reports. Wall Street Zen raised INVO Fertility to a “hold” rating in a report on Saturday, August 29th. Weiss Ratings restated a “sell (e+)” rating on shares of INVO Fertility in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, INVO Fertility currently has an average rating of “Moderate Buy” and an average target price of $20.00.

INVO Fertility Trading Down 0.5%

NASDAQ IVF traded down $0.00 during trading hours on Thursday, hitting $0.93. The company’s stock had a trading volume of 76,140 shares, compared to its average volume of 2,092,177. INVO Fertility has a twelve month low of $0.90 and a twelve month high of $84.40. The firm has a market capitalization of $2.33 million, a P/E ratio of -0.03 and a beta of 2.34. The company has a quick ratio of 0.67, a current ratio of 0.71 and a debt-to-equity ratio of 0.03. The stock has a fifty day moving average of $1.04 and a 200 day moving average of $1.84.

INVO Fertility (NASDAQ:IVF) last released its earnings results on Friday, August 14th. The company reported $0.35 earnings per share for the quarter. The firm had revenue of $2.18 million for the quarter. INVO Fertility had a negative return on equity of 85.54% and a negative net margin of 116.29%.

INVO Fertility Company Profile

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.